Core Viewpoint - The company expects to achieve a loss attributable to shareholders of no more than 1 million HKD for the fiscal year ending June 30, 2025, representing a significant reduction of approximately 95% year-on-year [1] Financial Performance - The company's financial performance has significantly improved during the reporting period, primarily due to several factors [1] - Business improvements led to a gross profit increase of approximately 9.2 million HKD or 184% year-on-year [1] - Enhanced cost control measures for administrative and operational expenses contributed positively [1] - The company recognized loan capitalization gains of approximately 3.9 million HKD during the reporting period [1] - Financing costs decreased due to the loan capitalization, further aiding financial performance [1]
国药科技股份发盈警 预期年度公司拥有人应占亏损不超过100万港元 同比大幅减少约95%